The overexpression of RARγ and its activation play roles in the abnormal behaviour of CSCs for a number of cancers that so far include some cases of AML, cholangiocarcinoma, colorectal, clear cell renal cell, hepatocellular, pancreatic ductal adenocarcinoma, prostate, and ovarian. Here, RARG is linked to pancreatic ductal adenocarcinoma.